UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the months of
July and August
Commission File Number: 001-41425
(Translation of registrant’s name into English)
Commission File Number:
Room503, Building C2, No. 1599
Xinjinqiao Road, Pudong New Area
Shanghai, China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Resignation of Director
Effective as of July 21, 2024, Mr. Travers Robert O’Keefe has resigned as a director and a member of the Nominating and Corporate Governance Committee of Golden Sun Health Technology Group Limited (the “Company”). Mr. O’Keefe’s decision to resign did not arise or result from any disagreement with the Company.
Appointment of Director
On July 31, 2024, the Board of Directors of the Company appointed Xu Xijing as a director and a member of the Nominating and Corporate Governance Committee of the Company, effective August 3, 2024. Xu Xijing is an independent director under the applicable rules and regulations of the Securities and Exchange Commission and rules of Nasdaq. Xu Xijing does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings with major shareholders, customers, suppliers or others, pursuant to which Mr. Kealey was selected as a director.
Financial Results
On August 2, 2024, the Company reported its financial results for the six months ended March 31, 2024 and 2023. The Company hereby furnishes the following documents as exhibits to this report: “Unaudited Condensed Consolidated Financial Statements of Golden Sun Health Technology Group Limited as of and for the Six Months Ended March 31, 2024” and “Operating and Financial Review and Prospects”.
1
EXHIBIT INDEX
| Exhibit Number |
Description of Exhibit | |
| 99.1 | Unaudited Condensed Consolidated Financial Statements of Golden Sun Health Technology Group Limited as of and for the Six Months Ended March 31, 2024 | |
| 99.2 | Operating and Financial Review and Prospects | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Golden Sun Health Technology Group Limited | |||
| By: | /s/ Xueyuan Weng | ||
| Name: | Xueyuan Weng | ||
| Title: | Chief Executive Officer | ||
Date: August 2, 2024
3